Key result
Rosiglitazone linked to incidental pulmonary hypertension in a case report.
Why the study?
Thiazolidinediones are associated with adverse reactions related to volume overload, but their relationship with pulmonary hypertension requires further clinical description.
Case Report (n=1)
No
Single case does not support practice change; leaves open possible rosiglitazone link to pulmonary hypertension.
Thiazolidinediones are currently indicated for the treatment of Type 2 Diabetes. This class of drugs has been associated with several adverse reactions associated with volume overload. This report describes a case of a 65 year old African-American female with a history of hypertension and obesity, and taking rosiglitazone (Avandia) for her Type 2 Diabetes whose evaluation for chest pain resulted in the incidental finding of pulmonary hypertension noted on echocardiogram. The subsequent evaluation, follow-up and treatment are discussed along with potential pitfalls and implications for clinical care.
No takes yet. Share an insight, caveat, or question.
Jeffrey E. Michaelson (2008) conducted a case report in Type 2 Diabetes (n=1). Rosiglitazone (Avandia) was evaluated on Pulmonary hypertension. A 65-year-old female taking rosiglitazone for Type 2 diabetes was found to have pulmonary hypertension incidentally during an evaluation for chest pain.